Pharmaceutical company Wockhardt won’t face a significant impact of the global turmoil over US tariffs due to its strong business model, according to the company’s founder and chairman, Dr Habil Khorakiwala. In an interview with NDTV Profit, Dr Khorakiwala expressed confidence in the company's business model that focuses on drugs and biologicals. The company’s exposure to the US market is just 5%, and it is planning to exit the generic business in the country soon.